Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova for Maintenance of Remission in Crohn's Disease
NCT00074542Phase 3Completed
- Sponsor
- Tillotts Pharma AG
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Epanova with Placebo (2 arms). Primary endpoint: Clinical Relapse at 1 year. Started Sep 2002; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00074542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074542.